Bacillus Anthracis Protective Antigen, Adsorbed

Summary

Bacillus Anthracis Protective Antigen, Adsorbed (CHEMBL6068494) is an approved unknown; indicated across 1 condition including anthrax infection.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Unknown
• Indications: 1 condition
• Clinical trials: 1

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL6068494
Name	Bacillus Anthracis Protective Antigen, Adsorbed
Type	Unknown
Max phase	4

Also known as: Bacillus anthracis protective antigen, adsorbed, Cyfendus, BACILLUS ANTHRACIS PROTECTIVE ANTIGEN, ADSORBED

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
anthrax infection	4	MONDO:0005119	EFO:0000778

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07268612	Not specified	NOT_YET_RECRUITING	Evaluation of Clinical Benefit and Safety Following CYFENDUS Administration for Post-Exposure Prophylaxis of Anthrax Disease.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).